LY-2109761
Identifiers
  • 4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H27N5O2
Molar mass441.535 g·mol−1
3D model (JSmol)
  • C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6
  • InChI=1S/C26H27N5O2/c1-2-9-27-22(4-1)26-25(24-5-3-11-31(24)29-26)21-8-10-28-23-18-19(6-7-20(21)23)33-17-14-30-12-15-32-16-13-30/h1-2,4,6-10,18H,3,5,11-17H2
  • Key:IHLVSLOZUHKNMQ-UHFFFAOYSA-N

LY-2109761 is a synthetic compound which acts as a potent and selective inhibitor for the growth factor receptor TGF beta receptor 1. It is used for research into conditions such as pulmonary fibrosis and cancer.[1][2]

See also

References

  1. ^ Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, et al. (April 2008). "LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis". Molecular Cancer Therapeutics. 7 (4): 829–840. doi:10.1158/1535-7163.MCT-07-0337. PMC 3088432. PMID 18413796.
  2. ^ Tan QY, Cheng ZS (2018). "TGFβ1-Smad Signaling Pathway Participates in Interleukin-33 Induced Epithelial-to-Mesenchymal Transition of A549 Cells". Cellular Physiology and Biochemistry. 50 (2): 757–767. doi:10.1159/000494241. PMID 30308508. S2CID 52966340.
This article needs additional or more specific categories. Please help out by adding categories to it so that it can be listed with similar articles. (August 2022)
Categories